Loading, Please Wait...
PHOENIX, Jan. 28, 2019 (GLOBE NEWSWIRE) -- The Uptick Newswire Stock Day Podcast welcomed BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. President, CEO, and Director of BioCorRx Inc Brady Granier and CFO Lourdes Felix talked with Stock Day’s Everett Jolly.
At the start of the interview Jolly asked about the National Institute on Drug Abuse (NIDA) grant and what it would mean to the company. Granier said they applied for the grant last year after they met with the FDA.
“We just received the notice of award on January 17th,” he said. He went on to discuss how they feel that this grant will cover most, if not all, of the development costs required to advance BICX102 through the regulatory process. BICX102 is the company’s sustained release naltrexone implant for the treatment of opioid use disorder.”
“We’ve been waiting for this for quite some time, it’s a huge validation for our company, this team and our product”, added Granier.
Next Jolly asked about the reverse split on the stock. Felix explained they filled out the NASDAQ application well over a year ago as previously disclosed to shareholders.
“The timing with regard to the reverse split now makes sense,” she explained. “We’ve been waiting on the NIDA grant for almost a year now, we were awarded the NIDA grant and it just put the company in a better position overall in executing on our strategy and executing on the goals that we set out to provide better shareholder value.”
She went on to say the plan is to get uplisted this year. Felix says they are progressing on that and everything else they have set out to do. Jolly then asked her how big the NIDA grant was and what were they going to use the money for.
“The NIDA grant is approximately $5.7 million and will cover the development of BICX102 over the next two years,” explained Felix.
Jolly then asked about the plans for the company for 2019. “Our team is coming back together to get this thing in full motion so that’s going to take up a lot of our time this year. A couple of other things we are excited about is that we are still evaluating this new molecule, VDM101. We hope to do more work on that in the next few weeks and months,” Granier said. He went on to say their weight loss program is coming along and they hope to launch that this year as well.
To hear the entire interview with Granier and Felix, listen to the Stock Day Podcast here: https://upticknewswire.com/featured-interview-ceo-brady-granier-of-biocorrx-inc-otcqb-bicxd/
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids, and can prevent opioid overdose following relapse. The second component of the program developed by BioCorRx Inc. is a Cognitive Behavioral Therapy (CBT) program tailored specifically for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, visit www.BioCorRx.com.
Crescendo Communications, LLC
(212) 671-1020 x304
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
About Uptick Newswire and the “Stock Day” Podcast
Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.